FDA panel narrowly recommends authorization of first antiviral to treat COVID-19
An FDA expert advisory committee narrowly signed off Tuesday on the first antiviral to treat COVID-19. The drug, molnupiravir from Merck and Ridgeback Biotherapeutics, is intended to be used in unvaccinated people at risk for severe COVID-19 within five days of the start of symptoms. The...